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1. Introduction 
Fabry disease (FD) is a lysosomal storage disorder caused by the deficient α-galactosidase A 
(α-gal A) activity. Fabry nephropathy typically progresses throughout the fifth decade to 
end-stage renal disease (ESRD) requiring hemodialysis and/or kidney transplantation. 
Except for ESRD development, a milder phenotype “renal variant” type is characterized 
with low plasma α-gal A activity. This survey improved the interest for FD screening among 
ESRD patients. After the description of this “renal variant” of FD, many studies were 
designed for ESRD patients. 
The prevalence of 0.24 – 0.36 % found in Brazil express the importance of Fabry disease 
investigation among ESRD patients without known cause. Routine screening of male 
hemodialysis patients would enable earlier identification of other family members who 
might benefit from specific clinical treatment. The analysis of other epidemiological 
characteristics of regular FD could be used for the screening and detection of other kindred 
who might benefit from specific therapy as well as their offspring. 
2. General aspects 
Like most rare diseases, Fabry disease has long been a mystery disease, typically afflicting 
men of all ages and ethnic groups. With a poorly understood etiology and a disease 
affecting all major organ systems, little treatment other than symptomatic management has 
been available until recently. A patient may see many different specialists over a period of 5 
to 10 years before an accurate diagnosis takes place. 
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Beginning in childhood, common symptoms include chronic or intermittent numbness; 
burning, tingling pain that can occur daily, usually in the fingers and feet; episodic pain that 
is incapacitating and may be brought on by stress, exercise, or temperature changes; 
recurring fever with elevated erythrocyte sedimentation rate; angiokeratomas that may 
appear in adolescence and increase as an adult; opacity of the corneal lens; inability to 
perspire; severe abdominal pain; and an intolerance to temperature (heat or cold) and 
exercise. The condition then progresses in adulthood to include renal, cardiovascular, 
cerebrovascular, and pulmonary complications that may lead to end-stage renal disease, 
stroke, myocardial infarction, breathing problems and obstructions, and more.  
In this review, we intend to explain the major aspects of Fabry disease and comment some 
points relatives to the characteristic of progressive renal failure in these patients. 
3. Epidemiological data 
Fabry disease is a rare inborn error with a recessive X-linkage inherited pattern (Desnick et 
al., 2001). The estimated FD incidence is between 1:40,000 and 1:117,000 in general 
population (Desnick et al., 2003; Rolfs et al., 2005). Previous reports about the prevalence of 
end stage FD males on dialysis was estimated between 0.22% and 1.2% in several 
populations (Nakao et al., 2003; Linthorst et al., 2003; Kotamko et al., 2004; Thadhani et al., 
2002; Grünfeld et al., 2003; Mehta et al., 2009). 
Three similar studies explain the prevalence of FD among end-stage renal disease (ESRD) 
males in Brazilian population (Delgado et al., 2007; Biagini et al., 2007; Porsch et al., 2008). All 
studies screened about 30-40% of total patients who were submitted to dialysis treatment in 
three different Brazilian States: Rio de Janeiro (RJ), Paraná (PR) and Rio Grande do Sul (RS). 
Both first and second studies (RJ and PR) observed the same FD prevalence (0.24%) and the 
third study (RS) observed a comparable value (0.36%). FD prevalence in all studies was 
small compared with the results obtained by Nakao and colleagues (1.2%) (Nakao et al., 
2003) and here it is important to note that many others studies never showed the same 
prevalence among hemodialysis patients.  In fact, even other study in Japanese population 
found a small prevalence (0.22%) of FD among male dialysis patients (Ichinose et al., 2005). 
In addition, according to the nationwide screening for FD among dialysis patients 
performed in Austria (Kotamko et al., 2004), FD prevalence was really low (0.161%). In Latin 
American others studies also described lower FD prevalence, akin to Peru (0.3%) (Tumialán 
et al., 2005) and Colombia (0.4%) (Martínez et al., 2005). These results support the idea that 
true FD prevalence is in average less than 0.5% among ESRD male and the overestimation in 
some studies may be related to small populations groups and/or a selection bias of the 
patients screened. Further studies are required in different ethnical groups with greater 
samples, especially among ESRD males with unknown cause for chronic renal failure. 
4. Genetic and biochemical outlines 
The enzymatic defect in FD results from the deficient activity of the α-galactosidase A (α-gal 
A), a lysosomal hydrolase encoded by a gene (GLA) localized to Xq22. The GLA gene is 12 
kb long and consists of 7 exons encoding 429 amino acids including a 31-amino acid signal 
peptide. The mature form of α-gal A is a homodimeric glycoprotein with molecular weight 
of ~46kDa synthesized from that point on cleavage of the signal peptides with ~50kDa 
(Bernstein et al., 1989).  
The primary substrate of this enzyme is globotriaosylceramide (galactosylα1 → 4galactosylβ1 
→ 4glucosylβ1 → 1’ceramide), and the failure of α-gal A activity increase the deposition of 
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glycosphingolipids with terminal α-linked galatocsyl moieties (Desnick et al., 2003). In FD 
this leads to progressive intracellular accumulation of glycosphingolipids, mainly in the 
form of globotriaosylceramide (Gb-3), in many cells, particularly in renal epithelial cells, 
endothelial cells, pericytes, vascular smooth muscle cells, cardiomyocytes, and neurons of 
the autonomic nervous system (Desnick et al., 2001). The Figure resume the cleavage events 
in Gb-3 to Gb-2 transition. 
The genetic defect occurs in all cell types, but involvement differs greatly among different 
organs and cell types. This heterogeneity likely reflects different rates of sphingolipid 
metabolism. Thus the minimum threshold requirement for α-gal A activity to prevent Gb-3 
accumulation varies across cell types due to the type and amount of substrates that are 
recycled by the different cells (Alroy et al., 2002).  
 
 
Fig. 1. Schematic representation of  α-gal A action in Gb-3 to Gb-2 cleavage into lysosomal. 
Renal lesions are found in both hemizygous (male) and heterozygous (female) patients. 
Renal symptoms in the latter are typically milder and delayed by 2 to 3 decades, but there is 
considerable variability (Gubler et al., 1978). Although the disease primarily affects men, the 
genetic mechanism responsible allows the defect to be passed on by women. However, as 
women were presumed to be protected to the effects of the disease, this disorder has not 
been studied as comprehensively in them. The variability is likely the result of the random 
nature of X inactivation, resulting in considerable variability in α-gal A activity among 
carriers and within one carrier individual among various tissues or regions of a single tissue. 
5. Clinical diagnosis markers 
Clinical onset of the disease typically occurs during childhood or adolescence with recurrent 
episodes of severe pain in the extremities, characteristic cutaneous lesions know as 
angiokeratomas and a distinctive but asymptomatic corneal dystrophy (Clarke et al., 1971). 
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Proteinuria and chronic renal disease occur with increasing age. Severe renal impairment 
leads to hypertension and uremia. Without dialysis, transplantation or enzyme replacement 
therapy (ERT), progressive renal failure is the main cause of death in the 4th decade of life in 
most hemizygous males with FD. However, a number of variants with residual α-gal A 
activity with late-onset manifestations primarily limited to the heart or kidney have been 
described (Desnick et al., 2001; Nakao et al., 1995; Meroni et al., 1997).  
The ‘classical phenotype’ includes the pain and paresthesias in extremities, diffused 
angiokeratoma and hypohidrosis during childhood or adolescence, and also corneal 
opacities and renal failure (Clarke et al., 1971; Desnick et al., 2004). Fabry nephropathy 
typically progresses throughout the fifth decade of life to ESRD requiring hemodialysis 
and/or kidney transplantation. In view of this fact, hemodialysis patients represent an 
important target group for FD screening (Desnick et al., 2003; Nakao et al., 1995). Death 
usually occurs due to renal failure, cardiac or cerebrovascular disease. In addition, milder 
variants with residual α-gal A activity have been described (Desnick et al., 2004; Nakao et al., 
1995). The cardiac and renal variants present with either late-onset manifestations primarily 
limited to the heart or kidney (Desnick et al., 2001; Meroni et al., 1997). 
Since the description of the ‘renal variant’ (Nakao et al., 2003), a milder FD phenotype with 
either late-onset manifestations primarily limited to the kidney, important dialysis screening 
efforts of ESRD populations have been carried out (Nakao et al., 2003; Linthorst et al., 2003; 
Torra et al., 2003; Kotamko et al., 2004; Thadhani et al., 2002) and seemed to be worthwhile 
since kidney failure is an important outcome in FD.  
While in an epidemiological point of view FD occurrence is low, on the other hand the FD 
diagnosis is very important for detection of family members. In view of this fact, dialysis 
patients represent an important target group for FD screening because they permit to 
identify FD patients and therefore others carriers among your family members. Each 
screened confirmed patient could allow early diagnosis of others related subjects, who can 
get treatment before or in the earlier symptoms manifestations. In these terms, FD screening 
among ESRD patients consists of an important tool for detection of FD patients and it could 
be followed by FD screening between family members of the index case. Both pedigree and 
population screening studies have been described and it can be carried out in 
subpopulations thought to be at higher risk of disease than the general population (Warnock 
et al., 2005).  
6. Guess of renal damage 
There are some references that the renal Gb-3 content, renal pathology and renal function 
correlate with residual α-gal A activity in leukocytes (Branton et al., 2002). If renal α-gal A 
activity correlates with leukocyte α-gal A activity (a reasonable but untested assumption), 
this suggests that residual enzyme activity in renal parenchymal cells retards progression of 
renal disease. One case report has suggested that renal α-gal A activity was reduced 
compared with liver α-gal A activity when each was expressed as a fraction of normal α-gal 
A activity in that organ; the mechanism for such a finding is unclear (Kano et al., 1974). 
Similarly, were found that Fabry patients with conservative missense mutations have 
delayed appearance of renal disease compared with patients with nonconservative missense 
mutations or others mutations those resulting in deletions, insertions, or premature stop 
codons (Branton et al., 2002).  
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According Alroy and colleagues (Alroy et al., 2002) three mechanisms might explain the 
segmental and global glomerulosclerosis that characterizes Fabry disease: microvascular 
disease, podoctyte injury, and tubulointerstitial injury. Gubler and colleagues (Gubler et al., 
1978) observed that in older Fabry patients, those 25 to 50 year old, the progressive renal 
pathologic changes in the glomeruli and tubulointerstitium may be related to ischemic 
change. These changes include glomerulosclerosis, often with wrinkled and partially 
collapsed glomerular basement membrane, tubular atrophy, interstitial fibrosis, and 
vascular thickening. These changes were generally absent or mild in patients under 25 year 
of age. In particular, these investigators noted that the earliest and most consistent 
degenerative alteration was arterial “fibrinoid” deposits and suggested that these were due 
to necrosis of smooth muscle cells fatally overloaded with Gb-3 deposits.  
Hypertension is not a common feature of Fabry disease, although it may occur with 
progressive renal dysfunction (Branton et al., 2002). Therefore, according Gubler and 
colleagues (Gubler et al., 1978), one mechanism of renal injury in Fabry disease is 
accumulation of Gb-3 within the arterial vessel wall and subsequent vascular compromise. 
In this regard, the renal vasculature is similar to the coronary and cerebral vessels, in which 
large vessel deposition of Gb-3 is associated with premature vascular disease that is 
responsible for premature death in many patients.  
Toxic accumulation of Gb-3 within the podocyte may constitute a second important 
mechanism of glomerular injury. Podocytes are highly differentiated cells; their foot 
processes and slit-diaphragms constitute a critical portion of the glomerular filtration barrier 
that retards the entry large molecules into the urinary space. These cells are post mitotic and 
fail to undergo proliferation under most pathologic circumstances (an exception being the 
collapsing variant of focal segmental glomerulosclerosis), which means that they generally 
are not replaced when they are lost due to lethal injury. Kriz and Lemley (Kriz & Lemlev, 
1999) have proposed that when podocytes are lost, the denuded glomerular basement 
contacts the parietal epithelial cells and forms a synechia. Within the synechia, there is 
activation and proliferation of cells, especially mesangial cells, the entry of immune cells, 
including macrophages, and the accumulation extracellular matrix protein. This repair 
response may be driven in part by the leakage from the circulation into the synechia of 
macromolecules, including cytokines, chemokines, and growth factors, via the impaired 
glomerular filtration barrier. Matrix expansion and subsequent collapse of the capillary loop 
appears as the focus of solidification. This constitutes the lesion of segmental 
glomerulosclerosis, which progresses to global glomerulosclerosis.  
The Gb-3 also induces podocyte injury, resulting in focal and ultimately global 
glomerulosclerosis. Deposition of Gb-3 within tubular epithelial cells may lead to focal 
tubular atrophy and interstitial fibrosis. As this process progresses, the glomeruli upstream 
of more severely affected tubules may function poorly or not at all. Other glomeruli may 
undergo hypertrophy to compensate, and hyperfiltration in these glomeruli may trigger a 
secondary form of focal segmental glomerulosclerosis. Evidence in support of this 
mechanism would include demonstration of glomerular enlargement, particularly in the 
early stages of glomerular and tubular injury in Fabry disease.  
Alternatively, Eng and colleagues (Eng et al., 2001a) proposed the change in microvascular 
inclusions in interstitial endothelial cells of kidney, heart, and skin as a primary endpoint in 
their recent trial of α-gal A replacement. But the importance of this parameter as a potential 
substitute marker for the progression of renal dysfunction (impaired GFR) and other renal 
pathology (glomerulosclerosis, interstitial fibrosis) is uncertain and needs to be tested in 
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longitudinal studies. Some additional pathologic markers, as mesangial expansion, 
glomerulosclerosis, and interstitial fibrosis were included in another trial of α-gal A 
replacement (Schiffmann et al., 2000), although these pathologic markers are also untested as 
appropriate markers for progressive renal functional decline in Fabry disease. 
7. Urinary concentration and proteinuria changes 
Urinary concentration defects may be the earliest functional manifestation of Fabry renal 
disease, leading to polyuria and nocturia. However, nephrology referral is more typically 
initiated by the development of proteinuria. Proteinuria may begin in the teenage years and 
becomes more frequent when patients reach their 20s and 30s. 
In the NIH series (Branton et al., 2002), 33 of 34 patients who had urine protein 
electrophoresis were found to have glomerular proteinuria, although the proteinuria did not 
usually reach nephrotic levels. Indeed, 23% of patients progressed to chronic renal 
insufficiency (CRI) without ever having nephrotic proteinúria and 50% of patients 
developed CRI by 43 year of age. The full presentation of nephrotic syndrome was not 
frequent even in those patients who developed nephrotic-range proteinuria. Only 26% of 
patients with nephrotic-range proteinuria developed hypoalbuminemia, and 21% developed 
hyperlipidemia. The onset of CRI may begin as early as the second decade of life. The mean 
age of onset of clinical nephropathy (CRI or proteinuria) has been reported as 27 year  
(Donati et al., 1987).  
End-stage renal disease was the most common cause of death in Fabry patients before the 
development of dialysis and renal transplantation and ESRD may rarely occur during the 
teenage years (Branton et al., 2002).  
Progression from onset of CRI to ESRD occur in mean of 4 ± 3 yr (range, 1 to 13 yr) and was 
not affected by patient age at onset of CRI or magnitude of proteinuria (Branton et al., 2002). 
Besides that, patients with undetectable residual α-gal A activity had higher scores for 
glomerular pathology (P = 0.027) and tubulointerstitial pathology (P = 0.007), and they also 
had higher concentrations of Gb-3 in kidney tissue (P = 0.039) (Branton et al., 2002).  
8. Improve in treatment in recent years 
Fabry patients with proteinuria or CRI should have aggressive treatment of hypertension is 
present and should probably be treated preferentially with angiotensin antagonist therapy; 
the latter recommendation is based on theoretical considerations, as definitely proof of 
efficacy has not been obtained yet. 
Two different recombination α-gal A preparations are in use for treating Fabry disease 
(Schiffmann et al., 2001a; Eng et al., 2001a). One enzyme is produced by Chinese hamster 
ovary (CHO) cells with classic recombinant technology (agalsidase β, Fabrazyme – Genzyme 
Corporation), and the other enzyme is produced by cultured human skin fibroblast with an 
activated  promoter of the α-gal A gene (Agalsidase α, Replagal – Shire Human Genetics 
Therapies). Both recombinant enzymes are quite comparable in properties and differ only 
alightly in glycan composition (Blom et al., 2003). The two enzyme preparations have 
independently been examined in clinical investigations and are both registered in Europe 
for treating Fabry patients. Although both enzyme therapies were found to result in the 
desired Gb-3 from endothelium, the clinical effects are not robust as anticipated. In some 
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patients, stabilization of renal function and improvenment in cardiac hypertrophy occurs 
upon therapy, but a considerable number experiences progressive complications (Vedder et 
al., 2007) 
The NIH carried out a double-blind, randomized, placebo-controlled study of recombinant 
α-gal A produced in a human cell line (Replagal; Shire Human Therapies) and administered 
by biweekly infusion to 26 male Fabry patients for 6 months (Schiffmann et al., 2001a). The 
primary endpoint of this study was a reduction in neuropathic pain. Significant reductions 
in the severity of “pain at its worst” and in the use of chronic pain medications were 
demonstrated. Enzyme replacement therapy was associated with relatively few side effects, 
chiefly mild transient infusion reactions, which became uncommon when the infusion 
duration was increased (from 20 to 40 min).  
In the same study of Schifmann and colleagues, histologic assessment of renal biopsy 
samples showed that enzyme therapy was associated with more normal glomeruli (P < 0.01) 
and fewer glomeruli exhibiting mesangial matrix widening (P < 0.01), as well a slight 
increase in segmentally sclerotic glomeruli (P < 0.05) and no change in the number of 
globally sclerotic glomeruli. There were relatively few globally sclerotic glomeruli; therefore, 
the overall effect was an improvement in glomerular architecture. There was no change in 
the composite scores for tubulointerstitial damage or glycolipid deposits (the latter was 
assessed on toluidine blue– stained sections as the sum of scores in podocytes, glomerular 
endothelial/mesangial cells, proximal tubular epithelial cells, distal tubular epithelial cells, 
extraglomerular vascular endothelial cells, and vascular medial cells). Interestingly, there 
was however a significant decrease in glycolipid deposits in vascular endothelial cells (P < 
0.002). Enzyme replacement therapy was associated with a significant fall in Gb-3 
concentrations in plasma and urine sediment, but the findings in kidney tissue biopsies 
were not significant (NS) (Schiffmann et al., 2001a). Six months of enzyme therapy had no 
consistent effect on proteinuria. With respect to the effect of enzyme replacement therapy on 
renal function, there was a trend toward a greater fall in GFR, measured by inulin clearance, 
with placebo compared with enzyme therapy (P = 0.27) (Schiffmann et al., 2001a). Thus, this 
results was encouraging but insufficient to demonstrate a definitive benefit of ERT with α-
gal A on kidney function in the group studied during a small period of treatment.  
In another study, Thofhern and colleagues (Thofhern et al., 2009),  available 9 patients (7 
male, 2 female) during the period between January 1, 2002, and  August 1, 2005. They were 
treated according to protocol, receiving 0.2 mg/kg agalsidase alfa IV every two weeks. Over 
the course of 36 months of ERT, there was no change in kidney function and 24-hour 
proteinuria. This suggests that agalsidase alfa may slow or  halt the progression of kidney 
disease when used before extensive kidney damage occurs. No significant side effects were 
observed with ERT during the course of this study. 
Recent results from an open-label extension of enzyme replacement in patients enrolled in 
the original trial of NIH showed that patients in the initial treatment group continued to 
have stable or improved renal function measured by inulin and creatinine clearance after 8 
months of enzyme therapy. In contrast, patients originally in the placebo group who had 
shown a decline in renal function demonstrated significantly improved inulin clearance and 
creatinine clearance after 12 months of enzyme replacement therapy (Schiffmann et al., 
2001b). Improved intracardiac conduction as evidenced by significant reduction of QRS 
complex duration in electrocardiogram (ECG) after 6 months of enzyme treatment was also 
noted. These new results with enzyme replacement are encouraging and results of 
continued therapy will be interesting to follow.  
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Eng and colleagues (Eng et al., 2001b) evaluated the efficacy of recombinant human a-gal A 
produced in Chinese hamster ovary cell line (Fabrazyme; Genzyme, Boston, MA) in Fabry 
patients. In an open-label, doseranging study involving 15 patients, these authors found that 
biweekly infusions given for 10 weeks was associated with reduced kidney Gb-3 content (5 
of the 15 patients underwent paired renal biopsies; no statistics given). On glutaraldehyde-
fixed, methylene blue–stained kidney biopsy tissue, there was reduced storage material in 
interstitial capillary endothelial cells and mesangial cells. There was a lesser degree of 
improvement or no improvement in tubular epithelial cells and glomerular podocytes.  
These results obtained by Eng and colleagues were used to design The International Fabry 
Disease Study, a double blind, randomized placebo controlled trial involving 58 male Fabry 
patients treated with biweekly intravenous infusions for 20 weeks, with the primary 
endpoint being clearance of interstitial capillary endothelial cell deposits (Eng et al., 2001a). 
Complete clearance of interstitial capillary endothelial cell deposits occurred in 20 of 29 of α-
gal A–treated patients and 0 of 29 placebo-treated patients (P < 0.001). Similar significant 
changes in endothelial cell deposits were seen in skin and heart capillaries. There was no 
beneficial effect on GFR assessed by inulin clearance after 20 weeks of ERT. There was a 
transient improvement in pain scores that did not persist to week 20, but pain results were 
no different than with placebo.  
However, after 11 months of additional open label treatment with agalsidase beta, the renal 
effects of this ERT were more completely evaluated: clearance of Gb-3 from glomerular 
endothelial cells, clearance from smooth muscle cells, mesangial cells and cortical interstitial 
cells, and some clearance from podocytes (Thurberg et al., 2002). These results showing a 
clear renal benefit with the ERT was followed by an extension for an additional 54 months of 
treatment with agalsidase beta: complete clearance from endotelial and other cells was 
maintained and renal function remained stable in all but six patients, in wich progressive 
disease was associated  with significant baseline proteinuria and more glomerular sclerosis 
(Germain et al., 2007). After that, agalsidase beta (Fabrazyme) was approved for marketing 
in Europe in 2001, and in the United States in 2003 with the main indication for the 
reduction in the accumulation of Gb-3 deposits in the capillary endothelium of the kidney. 
Agalsidase alfa (Replagal) is approved for marketing in Europe and many other countries. 
Both was recently approved for use in Brazil.  
Data from the phase IV trial with agalsidase beta in 82 adults with Fabry disease and renal 
dysfunction at baseline (creatinine concentration between 1.2 and 3.0 or estimated creatinine 
clearance less than 80 mL/min), randomly assigned in a two to one treatment to placebo 
ratio during 35 months, showed a trend to better clinical effect with treatment, although no 
statistically significant (Banikazemi et al., 2007). Importantly, a secondary analysis found 
benefits with therapy in those patients with renal function relatively well preserved 
(clearance ≥ 55mL/min/1.73m2) for those with renal function less than 55mL/min/1.73m2. 
In addition, an open label treating 58 patients with 1 mg/kg of agalsidase beta for 30 to 36 
months demonstrated that baseline proteinuria less than 1 g and glomeruloesclerosis less 
than 50% showed better evolution and better renal prognostic (Wilcox et al., 2004). All these 
data suggest that starting therapy before extensive renal damage has been identified might 
be beneficial for the prevention of progression to renal failure. 
In summary, some placebo-controlled clinical trials have shown that 6 months of enzyme 
replacement therapy with α-gal A is associated with improved glomerular architecture 
and/or reduced glycolipid deposits in the kidney, and one study also suggested 
improvement in renal function. These trials have recently been reviewed (Pastores et al., 
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2002). It makes sense that vascular endothelial cells are especially responsive to 
intravenously administered enzyme, in that these cells have direct access to the α-gal A 
present in the circulation. The majority of Gb-3 deposition in the kidney, however, does not 
appear to be within these cells. Indeed, Schiffmann and colleagues also demonstrated 
improved glomerular architecture, and results of follow-up studies of renal function are 
forthcoming (Schiffmann et al., 2001a/b).  
All the results of International Study of Fabry Disease with agalsidase beta, including 
double blind studies, open-label studies and extension studies has shown the best evidence 
of benefit on the renal function, with low rate of adverse events. Data of these studies 
demonstrated that 1mg/kg each other week of enzyme replacement are capable of stabilize 
the renal function mainly when the clearance is relatively well preserved (≥ 55 
mL/min/1.73m2), the glomeruli and possibly interstitial tissue is not extensive damaged 
and the proteinuria is less than 1 g per day.     
Additional studies as to whether α-gal A therapy can prevent, slow, halt, or reverse 
declining renal function in patients with Fabry disease will likely be of 1 year or longer 
duration, possibly selecting only patients with renal insufficiency for inclusion to maximize 
the chance of showing a benefit in renal function. Nevertheless, at the present time enzyme 
replacement therapy holds considerable promise for patients with Fabry disease with and 
without kidney involvement. 
9. Final considerations 
As treatment for Fabry disease is now available the enzyme replacement therapy. This 
treatment, among other benefits, reduced Gb-3 depositions in renal tissue and could 
represent a better outcome for FD patients. However, this approach is important if applied 
before the onset of ESRD when the efficiency of treatment is more evidenced.  
This fact also indicates the importance of FD diagnosis before the classical symptoms 
appear. A better awareness about FD among physicians and scientists should increase the 
number of patients that will be identified by different specialists and through population 
and family screening. Subsequently, FD diagnosis should be considered in every patient 
with unexplained renal disease, especially in patients with painful uncleared episodes, 
disseminate cutaneous lesions or when cardiac or cerebral complications suggest an 
underlying mutisystemic disorder. 
The results presented here stresses the importance of Fabry disease reports since a single FD 
diagnosed patient by screening is a potential indicator for finding others Fabry carriers 
within his family. Because enzyme replacement therapy by recombinant α-gal A has 
emerged as a promising means to prevent and remove Gb-3 deposition, it is now necessary 
to make this diagnosis earlier.  
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